TuHURA Biosciences, Inc.

HURA

$2.12

+0.73%

2026-09-04 12:30:02 EDT+$0.02

Healthcare

Biotechnology

NASDAQ

Active Trading

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is ...

Price Action of HURA

$2.12

+0.73%+$0.02

High—

Low—

52W High-38.3%

Rel. vol—

Interval

Range2.5h

Volume—SMA5SMA10

—

TuHURA Biosciences, Inc. (NASDAQ: HURA) is an immuno-oncology company focused on developing novel therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company has reached the critical Phase 3 registration stage of clinical development and is dedicated to pioneering innovative technologies that combat the mechanisms by which cancers ...TuHURA Biosciences, Inc. (NASDAQ: HURA) is an immuno-oncology company focused on developing novel therapeutics to overcome primary and acquired resistance to cancer immunotherapies. The company has reached the critical Phase 3 registration stage of clinical development and is dedicated to pioneering innovative technologies that combat the mechanisms by which cancers develop resistance to existing treatments. Its operations are based in Tampa, Florida. As of the latest data, the company has a market capitalization of approximately $136.9 million, with a stock price of $2.15. It employs 22 full-time employees. The company's lead technology includes three distinct product candidates aimed at different pathways of resistance. Financially, TuHURA has no revenue, as it is in the development stage, and it reports negative EBITDA and net income, reflecting its heavy investment in R&D. Key financial metrics include a return on equity of -154% and a debt-to-equity ratio of 0.02, indicating low leverage. The company's cash position is modest, with working capital of about $0.92 million. The CEO is James A. Bianco, a veteran of the biopharmaceutical industry with over 30 years of experience, who also founded CTI Biopharma. The company recently acquired Kineta, Inc. in June 2025, expanding its pipeline. TuHURA's website is www.tuhurabio.com, and it is listed on the NASDAQ Capital Market.ExpandCollapse

Founded

2013

Employees

CEO

James A. Bianco

Full Name

TuHURA Biosciences, Inc.

Sector

Healthcare

Industry

Biotechnology

ROE

-154.32%

Market Cap

$0.13B

Current Ratio

0.18

WACC

6.04%

ROIC

-759.48%

Contact Information

http://www.tuhurabio.com

+1 813 514 8373

10500 University Center Drive, Tampa, FL 33612

Key Metrics of HURA

Snapshot

Latest / TTM · 6 periods

Market Cap

$134.71M

ROCE

-138.7%

EV / EBITDA

-4.53x

+9.6% YoY

FCF Yield

-22.4%

+54.0% YoY

Cash Conversion Cycle

-47833.3d

Current Ratio

0.18

Quick take

TTM —

Current ratio below 1.0

Negative working capital

Financial Highlights of HURA

Profitability trend

Latest / TTM · 6 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-3.89x

n/a

Debt / Equity

0.02

n/a

Current Ratio

0.18

Dividend Yield

0.0%

Understanding

TTM —

Current ratio below 1.0

Interest coverage is weak

Calendar of HURA

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-0.13 · Revenue $0.00 · 2 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-0.14 · Revenue $0.00 · 2 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-0.55 · Revenue $10.53M · 3 analysts
Mar 30, 2027
Q1 FY2027 · Estimated results
Est. EPS $-0.15 · Revenue $0.00 · 1 analysts

Recent history

Aug 14, 2026
Q2 FY2026 · Results reported
EPS $-0.14 · Revenue $0.00
View filing
May 15, 2026
Q1 FY2026 · Results reported
EPS $-0.13 · Revenue $0.00
View filing
Mar 31, 2026
FY2025 · Annual results
EPS $-0.63 · Revenue $0.00
View filing
Nov 14, 2025
Q3 FY2025 · Results reported
EPS $-0.14 · Revenue $0.00
View filing
Jun 30, 2025
Q2 FY2025 · Results reported
EPS $-0.21 · Revenue $0.00
Mar 31, 2025
Q1 FY2025 · Results reported
EPS $-0.15 · Revenue $0.00

Financial Statements of HURA

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$0	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-30.1M	-38.6%	-22.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-27.7M	-87.4%	-96.6%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	3.3%	+141.0%	+11.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	0.78x	-78.8%	-84.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$27.4M	+37.0%	+6.9%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-0.63 vs -0.62	-2.2%	-0.14 vs -0.15	+8.7%
Revenue Surprise	$0 vs $7.0M	-100.0%	—	—

Insider Transactions of HURA

Acquisitions (A)

Since Dec 12, 2025

Disposals (D)

Since Dec 12, 2025

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
May 28, 2026	Bianco James A.	director, officer: Chief Executive Officer	Common Stock	D	150,000	—
Feb 12, 2026	Tendler Craig	director	Options (Right to Buy)	A	156,240	$1.29
Feb 12, 2026	Ng George K	director	Options (Right to Buy)	A	156,240	$1.29
Feb 12, 2026	MANUSO JAMES S J	director	Options (Right to Buy)	A	156,240	$1.29
Feb 12, 2026	List Alan	director	Options (Right to Buy)	A	156,240	$1.29

Leadership Team of HURA

6 executives

Name	Title	Compensation	Gender	Year Born	Status
James A. Bianco	President, Chief Executive Officer & Director	USD 1,115,095	—	1957	Active
Dan Dearborn	Executive Vice President of Finance & Chief Financial Officer	USD 544,036	Male	1967	Active
Patricia Lawman	Co-Founder	—	Female	—	Active
Michael Lawman	Co-Founder	—	Male	—	Active
Michael Krsulich	Head of Quality Assurance	—	Male	—	Active
Amanda Garofalo	Senior Vice President of Clinical Operations	—	Female	—	Active

Recent News of HURA

Seeking Alpha8/18/2026Neutral

TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript

MarketBeat8/14/2026Neutral

TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord

TuHURA Biosciences NASDAQ: HURA outlined plans for its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, highlighting an ongoing Phase III study of IFx in first-line advanced Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates.

PRNewsWire8/14/2026Neutral

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update.

PRNewsWire7/22/2026Neutral

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

TAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A.

PRNewsWire6/15/2026Neutral

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for Acute Myeloid Leukemia (AML) The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026 TAMPA, Fla., June 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the study of its TBS-2025 VISTA inhibiting antibody for the treatment of molecularly defined subsets of AML and other blood related cancers.

Historical Employee Count of HURA

Current

Change

+15.79%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	22	10-K	Mar 31, 2026	View
Dec 31, 2024	19	10-K	Mar 31, 2025	View
Jun 30, 2024	1	10-K	Oct 7, 2024	View
Jun 30, 2023	2	10-K	Sep 18, 2023	View
Jun 30, 2022	3	10-K	Sep 27, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

TuHURA Biosciences, Inc.